Is NCT06808048 recruiting in Minneapolis, MN?

Yes, NCT06808048 is currently recruiting participants at its Minneapolis, MN location. This chronic pain patients clinical trial is actively enrolling qualified participants.

How do I join the chronic pain patients clinical trial in Minneapolis?

To join this clinical trial in Minneapolis, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Minneapolis clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Chronic Pain Patients Clinical Trial in Minneapolis, MN

About This Chronic Pain Patients Study in Minneapolis

This study will assess cognition, neural function, and drug exposure in chronic pain patients who have been prescribed medical cannabis and will differentiate outcomes based on use of specific CBD-dominant versus THC-dominant treatment products. This longitudinal study will recruit medical cannabis users from local dispensaries. Each participant will complete a baseline assessment prior to the start of medical cannabis use, monthly phone calls to assess treatment adherence, and a four-month follow- up assessment. The aims of this project are: Aim 1. To assess impacts of medical cannabis compounds on executive functions, learning and memory in adults to determine whether cognitive impairments are evident after the onset of cannabis use; Aim 2. To assess the impacts of medical cannabis compounds on white matter microstructure, functional brain activity and functional connectivity; Aim 3. To differentiate change over four months in these outcomes as a function of (a) age and (b) pre-to-post-treatment changes in blood levels of cannabinoid compounds.

Sponsor: University of Minnesota

Who Can Participate

Inclusion Criteria

Medical cannabis users (n=120) will be required to

Be ages 35-65;

Be qualified for a medical cannabis prescription based only on a diagnosis of chronic pain; note that individuals can, in theory, utilize medical cannabis for more than one qualifying condition. People with orthopedic pain will be prioritized.

Have normal or corrected-to-normal vision and hearing;

Be free of current and past DSM-V-deﬁned substance use disorders; have \< 5 lifetime recreational uses of illicit drugs.

Have limited daily exposure to nicotine (e.g., no daily smokers/vapers; use of nicotine products fewer than 5 occasions weekly);

Willing to abstain from alcohol, nicotine, and other (non-treatment) drugs for 24 hours prior to study. Abstinence will be verified by breathalyzer and urine drug screening; must not test positive on breathalyzer and urine drug screenings for any nonprescribed psychoactive substance or for cannabis (at baseline);

Must be right handed as assessed by the Edinburgh Handedness Inventory;

Lifetime use of cannabis \< 15 times; no cannabis product use (recreational or therapeutic) within the past six months;

Able to schedule and complete a multi-hour single session protocol;

Have sufficient manual mobility to be able to complete computerized neurocognitive assessments;

Able to communicate with the researchers by phone during the four month pre-post assessment interval Pain patients who are not using medical cannabis (n=60) will be required to:

Be ages 35-65;

Suffer from a chronic pain condition that could qualify them for medical cannabis; People with orthopedic pain will be prioritized.

Have normal or corrected-to-normal vision and hearing;

Be free of current and past DSM-V-deﬁned substance use disorders; have \< 5 lifetime recreational uses of illicit drugs.

Have limited daily exposure to nicotine (e.g., no daily smokers/vapers; use of nicotine products fewer than 5 occasions weekly);

Willing to abstain from alcohol, nicotine, and other (non-treatment) drugs for 24 hours prior to study. Abstinence will be veriﬁed by breathalyzer and urine drug screening; must not test positive on breathalyzer and urine drug screenings for any non- prescribed psychoactive substance or for cannabis (at baseline);

Must be right handed as assessed by the Edinburgh Handedness Inventory;

Lifetime use of cannabis \< 15 times; no cannabis product use (recreational or therapeutic) within the past six months;

Able to schedule and complete a multi-hour single session protocol;

Have suﬃcient manual mobility to be able to complete computerized neurocognitive assessments;

Able to communicate with the researchers by phone during the four month pre-post assessment interval Within both groups, concomitant opioid use will be allowed as will other prescribed treatments. Controls will be matched to the cannabis group on age, sex, socioeconomic status (SES), type of pain condition (orthopedic pain will be targeted) and comorbid opioid use. All potential participants must indicate at the baseline enrollment that they have no immediate plans to relocate from the Twin Cities metro area (e.g., must be willing and able to participate in longitudinal assessment for a four-month period).

Exclusion Criteria

Cannot have a degenerative neurological condition or a neurological condition that impacts brain function (e.g., epilepsy);

No contraindications to MRI scanning;

No lifetime history of severe DSM-V psychopathology (psychotic disorders, bipolar disorder); if currently treated mood for anxiety disorders, must be stable;

No current pregnancy or pregnancy within the prior 3 months; cannot be lactating;

No cannabis product use (recreational or therapeutic) within the past six months;

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Minneapolis?

Yes, this clinical trial (NCT06808048) has an active research site in Minneapolis, MN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Chronic Pain Patients Treatment Options in Minneapolis, MN

If you're searching for chronic pain patients treatment options in Minneapolis, MN, this clinical trial (NCT06808048) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Minneapolis research site is actively enrolling participants for this clinical trial. You'll receive care from experienced chronic pain patients specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all chronic pain patients clinical trials near you to find additional studies recruiting in your area.

Chronic Pain Patients Clinical Trial in Minneapolis, MN

Expert Care in Minneapolis

IRB Approved

No-Cost Care

Apply for This Minneapolis Location

Why Participate?

Simple Process